Frontiers in pharmacologyOct 28, 2026

Molecular insights into how GLP-1 receptor drugs work in type 2 diabetes and obesity

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 29, 2026

Abstract

Genetic variation in GLP1R, TCF7L2, and other loci is associated with differences in glycaemic and weight outcomes following treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs).

Substantial inter-individual variability in GLP-1RA efficacy and tolerability may be influenced by genetic variation, metabolomic changes, and gut microbiota composition.
Pharmacometabolomic studies indicate involvement of lipid-related pathways, including glycerophospholipids and ceramides, with distinct drug-specific metabolic signatures.
GLP-1RAs are associated with changes in gut microbial composition, including taxa such as Akkermansia and Bacteroides, though the clinical significance of these changes varies.
Multi-omics and AI-based models may aid in predicting treatment response by combining genetic, metabolic, microbial, and clinical data.

Simplified

Glucagon like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the management of T2D and obesity. T2D clustering highlights distinct phenotypes that differ in GLP-1RA benefit. While they have markedly improved quality of life for many individuals, converging evidence indicates that genetic variation, metabolomic remodeling, and gut microbiota composition contribute to substantial inter-individual variability in GLP-1RA efficacy and tolerability. GLP-1RAs, in return, can variably affect the metabolome and microbiome composition in treated individuals. This review focuses on human multi-omics GLP-1RA intervention studies, complemented by relevant mechanistic preclinical evidence. Genetic variation in GLP1R, TCF7L2, and other loci has been associated with differences in glycaemic and weight outcomes, although most findings remain preliminary, inconsistent across populations, or not yet replicated. Pharmacometabolomic studies show recurrent of lipid-related pathways including, glycerophospholipids, sphingolipids, ceramides, amino acids, and bile acids, with drug-specific signatures. GLP-1RAs are also associated with changes in gut microbial composition, including taxa such as Akkermansia and Bacteroides, although the direction and clinical significance of these changes vary across studies due to methodological and population heterogeneity. Multi-omics and AI-based models show promise for predicting treatment response by integrating genetic, metabolic, microbial, and clinical data to supporting more effective and individualized therapy and advancing precision medicine.

Full Text

Full text is available at the source.

View Full Text ↗

Molecular insights into how GLP-1 receptor drugs work in type 2 diabetes and obesity

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief